PDCD1 and colorectal carcinoma: Another phase II clinical trial is currently ongoing (NCT04729322), aiming to assess the effect of FMT in combination with the re-introduction of anti-PD-1 therapy (Pembrolizumab or Nivolumab) in patients with metastatic dMMR CRC who had not previously responded to anti-PD-1 [134].